A citation-based method for searching scientific literature

T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
Times Cited: 103







List of co-cited articles
1438 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
330
38

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
284
34

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
97
31

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Alessandro Pocai, Paul E Carrington, Jennifer R Adams, Michael Wright, George Eiermann, Lan Zhu, Xiaobing Du, Aleksandr Petrov, Michael E Lassman, Guoqiang Jiang,[...]. Diabetes 2009
243
30

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
257
23

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
117
22

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz,[...]. Diabetes Care 2016
92
23

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Cristina B Guzman, Xiaotian M Zhang, Rong Liu, Arie Regev, Sudha Shankar, Parag Garhyan, Sreekumar G Pillai, Christof Kazda, Naga Chalasani, Thomas A Hardy. Diabetes Obes Metab 2017
51
41

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda,[...]. J Med Chem 2017
56
33

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
88
21

Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.
Tricia M Tan, Benjamin C T Field, Katherine A McCullough, Rachel C Troke, Edward S Chambers, Victoria Salem, Juan Gonzalez Maffe, Kevin C R Baynes, Akila De Silva, Alexander Viardot,[...]. Diabetes 2013
115
17


Fibroblast growth factor 21 mediates specific glucagon actions.
Kirk M Habegger, Kerstin Stemmer, Christine Cheng, Timo D Müller, Kristy M Heppner, Nickki Ottaway, Jenna Holland, Jazzminn L Hembree, David Smiley, Vasily Gelfanov,[...]. Diabetes 2013
136
16

The metabolic actions of glucagon revisited.
Kirk M Habegger, Kristy M Heppner, Nori Geary, Timothy J Bartness, Richard DiMarchi, Matthias H Tschöp. Nat Rev Endocrinol 2010
160
16

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.
R W Gelling, X Q Du, D S Dichmann, J Romer, H Huang, L Cui, S Obici, B Tang, J J Holst, C Fledelius,[...]. Proc Natl Acad Sci U S A 2003
357
16

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
116
16

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller, Susanna M Hofmann. Mol Metab 2017
52
30

Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
Megan E Capozzi, Richard D DiMarchi, Matthias H Tschöp, Brian Finan, Jonathan E Campbell. Endocr Rev 2018
51
31

Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease.
Brian Finan, Christoffer Clemmensen, Zhimeng Zhu, Kerstin Stemmer, Karine Gauthier, Luisa Müller, Meri De Angelis, Kristin Moreth, Frauke Neff, Diego Perez-Tilve,[...]. Cell 2016
93
16

Targeted estrogen delivery reverses the metabolic syndrome.
Brian Finan, Bin Yang, Nickki Ottaway, Kerstin Stemmer, Timo D Müller, Chun-Xia Yi, Kirk Habegger, Sonja C Schriever, Cristina García-Cáceres, Dhiraj G Kabra,[...]. Nat Med 2012
180
15


Islet α cells and glucagon--critical regulators of energy homeostasis.
Jonathan E Campbell, Daniel J Drucker. Nat Rev Endocrinol 2015
124
15

Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.
Jinrang Kim, Haruka Okamoto, ZhiJiang Huang, Guillermo Anguiano, Shiuhwei Chen, Qing Liu, Katie Cavino, Yurong Xin, Erqian Na, Rachid Hamid,[...]. Cell Metab 2017
70
21

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
182
15

Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake.
Jaimini Cegla, Rachel C Troke, Ben Jones, George Tharakan, Julia Kenkre, Katherine A McCullough, Chung Thong Lim, Nassim Parvizi, Mohamed Hussein, Edward S Chambers,[...]. Diabetes 2014
76
18

Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass.
Mark J Solloway, Azadeh Madjidi, Chunyan Gu, Jeff Eastham-Anderson, Holly J Clarke, Noelyn Kljavin, Jose Zavala-Solorio, Lance Kates, Brad Friedman, Matt Brauer,[...]. Cell Rep 2015
76
17

GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet.
Christoffer Clemmensen, Joseph Chabenne, Brian Finan, Lorraine Sullivan, Katrin Fischer, Daniela Küchler, Laura Sehrer, Teja Ograjsek, Susanna M Hofmann, Sonja C Schriever,[...]. Diabetes 2014
78
16

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
13

Insulin Secretion Depends on Intra-islet Glucagon Signaling.
Berit Svendsen, Olav Larsen, Maria Buur Nordskov Gabe, Charlotte Bayer Christiansen, Mette M Rosenkilde, Daniel J Drucker, Jens Juul Holst. Cell Rep 2018
89
14

Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation.
E Danielle Dean, Mingyu Li, Nripesh Prasad, Scott N Wisniewski, Alison Von Deylen, Jason Spaeth, Lisette Maddison, Anthony Botros, Leslie R Sedgeman, Nadejda Bozadjieva,[...]. Cell Metab 2017
74
16

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
683
12

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi, Mark D Erion, Jas Gidda, Nancy A Thornberry, Matthias H Tschöp,[...]. Biopolymers 2012
65
18

Glucagon is the key factor in the development of diabetes.
Young H Lee, May-Yun Wang, Xin-Xin Yu, Roger H Unger. Diabetologia 2016
70
17

The glucagon receptor is required for the adaptive metabolic response to fasting.
Christine Longuet, Elaine M Sinclair, Adriano Maida, Laurie L Baggio, Marlena Maziarz, Maureen J Charron, Daniel J Drucker. Cell Metab 2008
132
12

Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
553
12

Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis.
Jens J Holst, Nicolai J Wewer Albrechtsen, Jens Pedersen, Filip K Knop. Diabetes 2017
66
18

GLP-1/glucagon receptor co-agonism for treatment of obesity.
Miguel A Sánchez-Garrido, Sara J Brandt, Christoffer Clemmensen, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp. Diabetologia 2017
63
19

Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
63
19



A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Joachim Tillner, Maximilian G Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart,[...]. Diabetes Obes Metab 2019
50
24

Glucagon receptor antagonism induces increased cholesterol absorption.
Hong-Ping Guan, Xiaodong Yang, Ku Lu, Sheng-Ping Wang, Jose M Castro-Perez, Stephen Previs, Michael Wright, Vinit Shah, Kithsiri Herath, Dan Xie,[...]. J Lipid Res 2015
40
27

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
608
11

Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
74
14

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
267
11

Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.
Ivan Quesada, Eva Tudurí, Cristina Ripoll, Angel Nadal. J Endocrinol 2008
206
11

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans.
Mikkel Christensen, Louise Vedtofte, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2011
163
11

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
11


The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.